foxo4-dri senolytic human trial 2024 improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



